PSMA Imaging to Find Prostate Cancer Recurrence
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new imaging scan (POSLUMA) that uses a radioactive tracer to find prostate cancer that has come back or spread after initial treatment. The scan may help doctors plan radiation therapy more accurately for men with recurrent prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Prostate cancer that has come back (biochemically recurrent), diagnosed within the last 2 years
- Intermediate unfavorable or high-risk prostate cancer at original diagnosis
- Planning to receive or eligible for radiation therapy
- PSA level below 1.0 ng/mL
- Male, at least 18 years old
- Not currently taking hormone therapy (ADT) for prostate cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
This Phase 3 trial tests whether a special PET scan using 68Ga-PSMA-11 can detect prostate cancer that has returned after surgery or radiation, measured by rising PSA. If the scan works well, it may help doctors find where the cancer is coming back.
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
This trial tests whether a special PET scan called Posluma can better monitor prostate cancer after treatment. It is for men with intermediate-risk cancer that has not yet spread, who are candidates for a targeted therapy approach.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.